Starton Holdings, Inc.

Starton Holdings, Inc. has filed an S-1/A, Amendment No. 4, for its initial public offering (IPO) of 5,000,000 shares of common stock, with an estimated price range of $5.00 to $7.00 per share. The company intends to list its shares on the Nasdaq Capital Market under the symbol "STA." The proceeds will primarily fund product development for its lead candidates, STAR-LLD-SC and STAR-LLD-OCR, which are continuous delivery systems for lenalidomide targeting hematologic malignancies, and for general working capital. Starton Holdings is a clinical-stage biotechnology company focused on improving cancer treatments through proprietary delivery technologies.